Product Description: Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research[1][2].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Sam Jackson, et al. Six months interim analysis of the phase 2 study of AL001 in frontotemporal dementia patients carrying a granulin mutation. Alzheimer's & DementiaVolume 17: Drug Development./[2]Robert Paul, et al. AL001 Blocks the Sortilin/PGRN Interaction and is a Potential Therapy for FTD-GRN (4422). Neurology, April 13, 2021; 96 (15 Supplement).
Molecular Weight: N/A
Compound Purity: 95.00
Research Area: Cancer
Solubility: H2O
Target: Neurotensin Receptor
English
Deutsch
